Last reviewed · How we verify
NCT03076424: NI-MWG
The Effect of Nutrient Intake on the Microbiome, Weight, and Glucoregulation (NI-MWG)
trial testing no intervention used in Obesity in 19 participants. Completed in 31 December 2017.
31 December 2017
Quick facts
| Lead sponsor | North Dakota State University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 19 |
| Start date | 8 March 2017 |
| Primary completion | 31 December 2017 |
| Estimated completion | 31 December 2017 |
| Sites | 1 location across United States |
Drugs / interventions tested
- no intervention used
Conditions studied
- Obesity — all drugs for Obesity →
- Type2 Diabetes — all drugs for Type2 Diabetes →
Sponsor
North Dakota State University
Who can join
Adults 18 to 65, female only, with Obesity or Type2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to investigate a persons dietary intake and its effect on the gut microbiome and the association of those two variables on weight and glucoregulation. Specifically, the investigators will compare the gut microbiota, fasting glucose and insulin, c-peptide and hemoglobin A1-c in three groups of subjects: obese patients (BMI ≥ 30 kg/m2) with type 2 diabetes mellitus (T2DM), obese patients without T2DM, and normal weight lean controls without T2DM. Each patient will also complete a detailed dietary recall (ASA-24) to investigate the association with diet, microbiome and weight/glucoregulation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03076424
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other North Dakota State University trials
Trials by the same sponsor.
- NCT05396196 — An Analysis of Kinesio® Tape With Manual Fascial Glide Application on Trigger Points in The Iliotibial Band · NA · completed
- NCT05395572 — The Effects of Kinesio® Tape on Neck Pain and Disability · NA · completed
- NCT04769063 — An Analysis of Kinesio® Tape on Mitigation of Dynamic Knee Valgus · NA · completed
- NCT04461184 — The Great Plains Internet Wellness Study for Aging · NA · completed
- NCT04531306 — An Analysis of Kinesio® Tape on Myofascial Pain Syndrome of the Iliotibial Band · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03076424 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by North Dakota State University
- Last refreshed: 23 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03076424.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing